Latest Biome Australia (ASX:BIO) News

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.

Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.

Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

Biome Australia has reported record-breaking sales revenue for FY25, driven by strong domestic demand and promising international expansion. The company is on track to deliver its first full-year net profit and meet ambitious growth targets.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Biome Australia is set to expand its Activated Probiotics range with two new products targeting vaginal health and perinatal care, tapping into a booming women’s health supplements market.

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.